three years of metformin threads, summarised so you do not have to read them
The title is the argument: three years of metformin threads, summarised so you do not have to read them. Here is the rest of it. Variability dropped before the average did, which was visible on the sensor and invisible on the lab result. Assumed the weight endpoints from the obesity trials applied to my situation.…
Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low. Risk rises with agents that act independently of glycaemia.
I would not compare your numbers to that population. Different baseline, different regimen, different trial.
[deleted]
variability matters as much as the mean
Time in range told me far more than the average did. Two quarters with the same A1c looked completely different on the sensor.
Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low.
Disagreeing with this line: that endpoint is from the obesity programme and does not answer the question.